Posted by Michael Wonder on 24 Nov 2016
Proposed cap on the R&D tax incentive will hamper clinical trials
22 November 2016 - The proposed $2 million cap on the R&D tax incentive will seriously damage clinical trials activity in Australia, should the Federal Government proceed with the measure.
Despite years of building momentum for Australia as an internationally competitive destination for early access to new treatments and medical devices and its associated economic benefits, capping the Incentive for clinical trials and related R&D will impact the industry.
